Parnell Pharmaceuticals Holdings Ltd. (PARNF)

[louman18]

That should read refinanced their debt.

[louman18]

anybody out there notice parn refinanced thir date and just released a pretty good report. Not bad for a 64 cent stock.

[MaineMan5]

'18 guidance had both good and bad to it - good: 30-35% rev growth in '18, $5-6mm EBITDA (about $.30 / share) caompared to breakeven this year, current SP at 2x expected '18 EBITDA, 100% rev growth in contract manufacturing, talk of maximizing shareholder value. Bad: boardroom drama, zydax change of strategy, pipeline uncertainty, some underperforming segments. I feel like even with the uncertainties however, this is a good risk / reward and remains in my speculative portfolio. Plan on holding for a few more quarters to see what transpires as it could be a home run, in any event, I don't see a lot of downside, and could easily be a $2-$3 stock at this time next year.

[kylegar15]

Agreed. I wish the CEO stayed on and executed a transaction. Hope we hear something in Jan.

[MaineMan5]

Someone at the Yahoo board said it was 74% for and 26% against and there would be a company update in January. Don't know how credible the poster is, but someone seems to have liked the decision based on the stock price today, or feels that some positives to the SP will accrue from all this. I wish shareholders had a better grasp as to what direction the company is going. The CEO letter was helpful, and laid out a pretty good case of voting against it, which I did. The company needs to now articulate how whatever action they take will benefit shareholders, and what their strategy is for the company and maximizing SH value. They have a nice little company here with several positives going for it (existing revenues are growing, Zydax for animals and possibly humans, state of the art manufacturing facility that started production in '17 and that the company previously stated was worth about $50 million, or $2.70 or so per share). I have been holding over a year, and hopefully 2018 will be the year in which shareholders are rewarded somehow.

[kylegar15]

Results from vote?

[MaineMan5]

wow - what happened? Is this about kicking Robert Joseph off the Board? This company had a pretty good future, I thought. Sounds like there is some intrigue behind the scenes. Besides not communicating with shareholders, they were doing well, growing nicely, and had some catalysts potentially coming the end of this year. I have about 10 thousand shares and plan to hold.... unless BKPT is imminent or something just as bad. But anything having a material effect on the business should be disclosed. Filing this away and hope it bounces back after this blows over.

[willlbone]

Turkey day comes early.

[kylegar15]

I've been following KIN since the 3s I will take a closer look thank you!

[kylegar15]

Exactly IPOd for 65M at 200M valuation I believe they will get back to that once they get zydax on the market Sign more commercial manufacturing contracts and partner zydax for human use.

[MaineMan5]

I totally agree, and if I recall, I don't think PARNF was originally intending to use Zydax on humans, as it is currently in use in many other countries for animals. Would be a great kicker if they could get it approved for humans though. While that would take longer (they have mentioned possible partnerships before) to get approval for humans, I still think the animal business alone is worth at least 10 times more than current share price. They have valued their lab alone at around $50 million, or about $2.75 share. I also have a stake in KIN, which expects one approval by end of year and one by mid next year, has a great mgt team, and 20 drugs in pipeline. Good overview of company from their Sept 27 investor presentation:
https://seekingalpha.com/article/4109903-kindred-biosciences-kin-presents-ladenburg-thalmann-2017-healthcare-conference-slideshow

[kylegar15]

Zydax for human use is a big one imo

[kylegar15]

I agree on everything. Been here for a while and got my average down pretty good. So many catalysts this quarter I hope they can execute! Stock is worth much higher imo if they can! Zydax alone. Looking forward to the upward movement that I hope will come pretty soon. Good luck to you.

[MaineMan5]

hey - another parnf supporter! - I had not seen anything about reporting today. I know previously they said they would only formally report with details every 6 months but I think they indicated they would give a summary to keep in contact with shareholders every 3 months. Here's what they said after 1st Q:

"Consistent with being a foreign private issuer, we only release full financials each half year, so we will focus today on the results of our business performance for the first three months of 2017 and provide additional updates."

Full 1st Q transcript:
https://seekingalpha.com/article/4076321-parnell-pharmaceuticals-holdings-parn-business-results-update-conference-transcript

I have been patiently holding for just over a year now (average price about $1.00) waiting for the catalysts that are supposedly coming by year end, especially Zydax. If you watch the stock on a daily basis, the last few weeks there is always a sale just after opening to lower the price several cents and then at the end of the day, a purchase is made to bring it back near where it started. Manipulated yes, but I don't trade it - I am a holder and will ride the ups and downs (mostly downs this year) as I really think when/if news breaks (hopefully soon), the stock price could go up very quickly. Other than taking the listing off Nasdaq and putting it on pink sheets (which I know saves them about $4 million / year they claim), this company has done what they say, showed solid growth, and is ready to make the next move if they can get some following and good news. Good luck!

[kylegar15]

Agreed. Quarterly call today after bell? I got a notification saying so. But I thought they reported every 6 months.

[MaineMan5]

Sleeper with tremendous potential. Revenue growth of 25% to $10.3mm last qtr, substantial improvement in profitability for first half of 2017. Ramping up development of PAR122 and PAR121 rest of year, PAR122 does not require FDA approval process. New contract manufacturing agreement in May 2017 that is a multi-million dollar, multi-year agreement. Turning EBITDA positive in 4th Q. Meetings with FDA and EMA in Oct. on Zydax. If don't need more data, could be approved by year end. Already being used in many countries with millions of doses. Possible human applicability. Manufacturing facility itself valued by company on recent call at approx $50 million ($2.77 share). Not thrilled they voluntarily moved to pink sheets (saves company $6 million year), but has had the desired effect. Upcoming catalysts on drugs and manufacturing. I would encourage everyone to read the detailed latest quarter business results at:

https://finance.yahoo.com/news/parnell-pharmaceuticals-holdings-ltd-announces-143000455.html

[tjguy]

Guessing 70% drop to 40 cents.

Should have backed up the truck and loaded up at those levels!!! WOuld have been a quick double and more!

Still a good deal even at $1.30 Might have to get some more.

[Renee]

PARN changed to PARNF:

http://otce.finra.org/DLSymbolNameChanges

[Renee]

PARN delisted from the Nasdaq to the OTC:

http://otce.finra.org/DLAdditions

[willlbone]

Vol/Delisting. Guessing 70% drop to 40 cents.

[otcmoneydoubler]

PARN MOVING ON 20M CONTRACT WITH SANOFI

[carolinacoast]

16 dollar target for the year, still

http://www.bodyconfidential.com/weekly-dish/earnings-outlook-on-parnell-pharmaceuticals-holdings-ltd-nasdaqparn/78116/

[ClarkKant]

Solid day so far here, looking for more next week! Could be the start of a multi-day gainer here.

[crudeoil24]

Some solid catalysts moving PARN.

[ClarkKant]

WAtch for the $2.66's dip, day one of a nice climb IMO.

[Wildbilly]

Parnell Pharmaceuticals Holdings Reports Q3 Loss A$0.18 Vs Loss A$0.11


FORM 6-K
http://stocknewsflow.com/1603429_000117184315005623_0001171843-15-005623

[Wildbilly]

Parnell Pharmaceuticals Holdings Upgraded to “Hold” by Zacks (PARN)

Posted by Stephan Byrd on Oct 14th, 2015

Parnell Pharmaceuticals Holdings logoParnell Pharmaceuticals Holdings (NASDAQ:PARN) was upgraded by Zacks from a “sell” rating to a “hold” rating in a research report issued on Wednesday, Marketbeat reports.

According to Zacks, “Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell’s premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia. “

Separately, Piper Jaffray restated a “buy” rating and issued a $12.00 target price (down previously from $16.00) on shares of Parnell Pharmaceuticals Holdings in a research report on Wednesday, August 12th.


Parnell Pharmaceuticals Holdings (NASDAQ:PARN) traded down 1.8844% during trading on Wednesday, hitting $3.6499. The stock had a trading volume of 404 shares. The company has a market capitalization of $52.83 million and a price-to-earnings ratio of 11.1960. Parnell Pharmaceuticals Holdings has a 12-month low of $3.20 and a 12-month high of $6.00. The stock has a 50 day moving average price of $3.88 and a 200 day moving average price of $4.32.

Parnell Pharmaceuticals Holdings (NASDAQ:PARN) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.07. Equities research analysts forecast that Parnell Pharmaceuticals Holdings will post ($0.87) earnings per share for the current year.

Parnell Pharmaceuticals Holdings Ltd. is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product and research and development of pharmaceutical products for global animal health markets. It operates in four segments: Companion Animal, which covers its Osteoarthritis portfolios across both Canine and Equine species; Production Animal-U.S., which covers its Reproductive Hormone portfolio across Production Animal in the United States of America; Production Animal-Rest of World, which covers the its reproductive hormone portfolio in Production Animal across all regions outside of the United States of America and Manufacturing Operations is responsible for the operation its Food and Drug Administration approved sterile manufacturing facility and the manufacture and release of all its pharmaceutical products.


http://www.tickerreport.com/banking-finance/861066/parnell-pharmaceuticals-holdings-upgraded-to-hold-by-zacks-parn/

[Wildbilly]

PARN: Zydax Top-Line improvement for osteoarthritis in dogs

in a pivotal clinical efficacy trial.

Parnell Pharmaceuticals Holdings Ltd Announces Positive Top-Line Pivotal Trial Results for Zydax(R), Disease-Modifying Osteoarthritis Drug in Dogs - Yahoo Finan...
https://finance.yahoo.com/news/parnell-pharmaceuticals-holdings-ltd-announces-110000720.html

[EagleD]

$PARN Great news all around! Bought in yesterday and looking for some movement today.

[Wildbilly]

PARN: Announces $11 Million Secured Term Loan Facility

Parnell Pharmaceuticals Holdings Ltd Announces $11 Million Secured Term Loan Facility - Yahoo Finance
http://finance.yahoo.com/news/parnell-pharmaceuticals-holdings-ltd-announces-113000266.html

[Wildbilly]

PARN: Positive Top-Line Pivotal Trial Results for Zydax(R)

Parnell Pharmaceuticals Holdings Ltd Announces Positive Top-Line Pivotal Trial Results for Zydax(R), Disease-Modifying Osteoarthritis Drug in Dogs - Yahoo Finan...
http://finance.yahoo.com/news/parnell-pharmaceuticals-holdings-ltd-announces-110000720.html

[Wildbilly]

PARN 1 yr anniversary of their IPO Thurs.

It looks like well established resistance $5.75-5.80ish just ahead.

I ran into this pre IPO article again from an esteemed stock "guru" at SA and thought I'd post it here for posterity.

http://bit.ly/1LeLfCu

[fred1963]

Thanks Wildbilly



for all the great info, I like what I see so far. I guess it's just you and I for now. ha ha I expect that to change though.

Good luck

[Wildbilly]

Nice march up the last month

building towards their Inaugural Investors Day June 18 where they are expected to release data from Zydax (pentosan polysulphate) phase III for canine osteoarthritis.

I'm thinking ZYDAX (fascimile} will find it's way into human trials eventually, I see no reason why not, the human joint is a larger easier target and we 'STAY' (hold still) better. ;)

Parnell Pharmaceuticals Holdings Ltd to Host Inaugural Investor Day on June 18, 2015 - Yahoo Finance
http://finance.yahoo.com/news/parnell-pharmaceuticals-holdings-ltd-host-123000418.html

and the JMP Securities HealthcareConference the 22nd, both will raise awareness among Institutions

http://finance.yahoo.com/news/parnell-pharmaceuticals-holdings-ltd-participate-123000653.html

[fred1963]

Jefferies PT target of $18 & Buy rating Parnell Pharmaceuticals(NASDAQ: PARN) June 12th 2015


Just going to need a little patience on this one. This stock and board remind me a lot of AVXL. When I first bought AVXL at .17 it traded minimal volume and the message board was completely dead. Now it is one of the hottest boards and stock around. I think the same could happen here, just need to get the word out, twitter is a good avenue for that.

Good luck, and again JMHO

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114612179

[Wildbilly]

PARN: 06/18/2016 New Efficacy Data for Zydax(R)

and Product Pipeline Updates

Parnell Pharmaceuticals Holdings Ltd to Host Inaugural Investor Day on June 18, 2015 - MarketWatch

Parnell Pharmaceuticals Holdings Ltd PARN, +4.92% a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that the company will hold its first Investor Day event for the institutional investment and research analyst community on Thursday, June 18th, 2015 in New York City. Registration begins at 8 am and the formal presentation and webcast will began at 8:30 am Eastern time.

Management will present results from the Pivotal Efficacy Clinical Study of Zydax®, Parnell's disease-modifying osteoarthritis therapy for dogs and horses, as well as global commercialization plans for Zydax and Glyde®, Parnell's nutraceutical product for osteoarthritis management. The program will feature in-depth presentations by Parnell's executive team on development progress in Parnell's new product pipeline, and noted industry experts will provide insights into new and emerging markets in the animal healthcare industry.

The event will be hosted by Chief Executive Officer Robert Joseph and Chief Scientific Officer Edward Robb, DVM, MS, DAC, VN, as well as featured expert speakers:

Chris Ragland, Chief Executive Officer, Animaltyix: The largest provider of syndicated market data will present an overview of the market size of various animal health industries
Professor Duncan Lascelles, BSc, BVSc, PhD, CertVA, DSAS(ST), DECVS, DACVS, North Carolina State University, College of Veterinary Medicine, and preeminent Key Opinion Leader on pain and mobility in dogs
Qualified institutional investors and research analysts may register to attend the Parnell 2015 Investor Day by contacting Karen Bergman or Susan Pietropaolo, BCC Partners at [e-mail] or [e-mail].

Parnell invites the public to listen to the presentations via a live webcast that will be accessible under the Investor Relations section of the company's website, http://investors.parnell.com/events.cfm. Parnell will maintain an archived replay of the webcast on its website for 30 days after the conference.

http://www.marketwatch.com/story/parnell-pharmaceuticals-holdings-ltd-to-host-inaugural-investor-day-on-june-18-2015-2015-06-01-81843026

.

[Wildbilly]

PARN CEO Comments on Q1, Nice Guidance

Parnell Pharmaceuticals' (PARN) CEO Robert Joseph on Q1 2015 Results - Earnings Call Transcript | Seeking Alpha

http://seekingalpha.com/article/3091806-parnell-pharmaceuticals-parn-ceo-robert-joseph-on-q1-2015-results-earnings-call-transcript

.

[Wildbilly]

PARN 6-K First Ever Net Profits,

small, but hey...

http://stocknewsflow.com/1603429_000117184315002088_0001171843-15-002088

.

[Wildbilly]

I love the space, just keeps getting bigger

Missed the boat on P_TX and I created the Ihub board. :(



.

[soseano]

Zacks gives "STRONG BUY". PT of $15.88. Great Entry here

[Wildbilly]

BlackRock, Inc. Adds To Parnell Pharmaceuticals Holdings

BlackRock, Inc. just filed a 13G "Statement of acquisition of beneficial ownership". BlackRock, Inc. now owns 878,722 shares of Parnell Pharmaceuticals.

This represents 6.6% of Parnell Pharmaceuticals.

http://www.sec.gov/Archives/edgar/data/1603429/000021545715000465/0000215457-15-000465-index.htm

.